These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 18775064)

  • 1. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis.
    Ziemssen T; Hoffman J; Apfel R; Kern S
    Health Qual Life Outcomes; 2008 Sep; 6():67. PubMed ID: 18775064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study.
    Jongen PJ; Lehnick D; Koeman J; Frequin S; Heersema D; Kornips B; Schyns-Soeterboek A; Visser LH; Schiphof P; Valkenburg A; Hiel J;
    J Neurol; 2014 Aug; 261(8):1469-76. PubMed ID: 24792727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of immunomodulatory treatment on multiple sclerosis fatigue.
    Metz LM; Patten SB; Archibald CJ; Bakker JI; Harris CJ; Patry DG; Bell RB; Yeung M; Murphy WF; Stoian CA; Billesberger K; Tillotson L; Peters S; McGowan D
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1045-7. PubMed ID: 15201369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
    Ziemssen T; Calabrese P; Penner IK; Apfel R
    J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
    Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
    Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary.
    Fricska-Nagy Z; Füvesi J; Rózsa C; Komoly S; Jakab G; Csépány T; Jobbágy Z; Lencsés G; Vécsei L; Bencsik K
    Mult Scler Relat Disord; 2016 May; 7():26-32. PubMed ID: 27237753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.
    Hadjimichael O; Vollmer T; Oleen-Burkey M;
    Health Qual Life Outcomes; 2008 Nov; 6():100. PubMed ID: 19014588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
    Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
    Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group.
    Liu C; Blumhardt LD
    J Neurol Sci; 2000 Dec; 181(1-2):33-7. PubMed ID: 11099709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
    Ramtahal J; Jacob A; Das K; Boggild M
    J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy with glatiramer acetate for multiple sclerosis.
    Munari L; Lovati R; Boiko A
    Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.
    Jongen PJ; Lehnick D; Sanders E; Seeldrayers P; Fredrikson S; Andersson M; Speck J;
    Health Qual Life Outcomes; 2010 Nov; 8():133. PubMed ID: 21078142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.
    Lebrun-Frenay C; Moulignier A; Pierrot-Deseilligny C; Benrabah R; Moreau T; Lubetzki C; Monchecourt F;
    J Neurol; 2019 Apr; 266(4):888-901. PubMed ID: 30730008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness of glatiramer acetate in clinical practice conditions.
    Arnal-García C; Amigo-Jorrin Mdel C; López-Real AM; Lema-Devesa C; Llopis N; Sanchez-de la Rosa R;
    J Clin Neurosci; 2014 Dec; 21(12):2212-8. PubMed ID: 25257663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
    Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
    Fernández-Fournier M; Tallón-Barranco A; Chamorro B; Martínez-Sánchez P; Puertas I
    BMC Neurol; 2015 Aug; 15():141. PubMed ID: 26286576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.